| Literature DB >> 25670809 |
Mirjam B Zeisel1, Julie Lucifora2, William S Mason3, Camille Sureau4, Jürgen Beck5, Massimo Levrero6, Michael Kann7, Percy A Knolle8, Monsef Benkirane9, David Durantel2, Marie-Louise Michel10, Brigitte Autran11, François-Loïc Cosset12, Hélène Strick-Marchand13, Christian Trépo14, Jia-Horng Kao15, Fabrice Carrat16, Karine Lacombe16, Raymond F Schinazi17, Françoise Barré-Sinoussi18, Jean-François Delfraissy19, Fabien Zoulim14.
Abstract
HBV infection is a major cause of liver cirrhosis and hepatocellular carcinoma. Although HBV infection can be efficiently prevented by vaccination, and treatments are available, to date there is no reliable cure for the >240 million individuals that are chronically infected worldwide. Current treatments can only achieve viral suppression, and lifelong therapy is needed in the majority of infected persons. In the framework of the French National Agency for Research on AIDS and Viral Hepatitis 'HBV Cure' programme, a scientific workshop was held in Paris in June 2014 to define the state-of-the-art and unanswered questions regarding HBV pathobiology, and to develop a concerted strategy towards an HBV cure. This review summarises our current understanding of HBV host-interactions leading to viral persistence, as well as the roadblocks to be overcome to ultimately address unmet medical needs in the treatment of chronic HBV infection. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.Entities:
Keywords: HEPATITIS B
Mesh:
Substances:
Year: 2015 PMID: 25670809 DOI: 10.1136/gutjnl-2014-308943
Source DB: PubMed Journal: Gut ISSN: 0017-5749 Impact factor: 23.059